Catalyst Pharmaceutical Inc.
CPRXCatalyst Pharmaceuticals, Inc. (CPRX) is a biopharmaceutical company focused on developing and commercializing therapies for rare neurological and neuromuscular diseases. The company's flagship product is Firdapse, used to treat Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disorder affecting nerve-muscle communication. Catalyst is dedicated to advancing treatments for patients with rare conditions through innovative research and development.
Company News
Jeffrey Del Carmen, Chief Commercial Officer of Catalyst Pharmaceuticals, exercised and sold 10,983 shares for approximately $256,200 on November 26, 2025, reducing his direct holdings by roughly 74%. The sale occurred following the company's strong Q3 results with revenues up 17.4% year-over-year and raised full-year guidance. While exercise-and...
Long-term study of AGAMREE in Duchenne muscular dystrophy patients reveals comparable effectiveness to standard corticosteroids, with significantly lower rates of vertebral fractures and better growth maintenance over five years.
Santhera Pharmaceuticals reported positive long-term data for AGAMREE, showing comparable effectiveness to standard corticosteroids in treating Duchenne Muscular Dystrophy, with improved safety profile and reduced side effects like growth suppression and vertebral fractures.
Catalyst Pharmaceuticals and SERB S.A. reached a settlement with Lupin Pharmaceuticals regarding patent litigation for FIRDAPSE, allowing Lupin to market a generic version starting February 2035, with ongoing litigation against Hetero still pending.
Santhera Pharmaceuticals will provide an update on the commercial progress of its drug AGAMREE for the treatment of Duchenne Muscular Dystrophy, as well as outline its strategic plans for further market expansion and diversification of its rare disease portfolio.
